Stockscreener 앱 받기
3.085
2.45%
0.075
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Enterprise value to EBIT forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
CABA Stock Draws Scrutiny As Ownership Filings Shift - timothysykes.com
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Cabaletta Bio (CABA) Stock Forecast & Analyst Ratings - Moomoo
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell Small Cap Completeness Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Index - marketscreener.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA) - TradingView
CABA Forecast — Price Target — Prediction for 2027 - TradingView
CABACabaletta Bio Inc Volatility & Greeks - Finviz
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup - Insider Monkey
CABA Technical Analysis & Stock Price Forecast - Intellectia AI
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Cabaletta Bio Shareholders Approve Share Increase and Directors - The Globe and Mail
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio | 4: Statement of changes in beneficial ownership of securities-Director Bollard Catherine - Moomoo
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Business Wire
CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption - TradingView
CABA: Rese-cel shows durable, safe, drug-free responses, enabling rapid outpatient adoption and expansion - TradingView
Cabaletta Bio Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa
CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com
1.67%
3.59%
자본화:
|
볼륨(24시간):